Patent Assignment
Reel/Frame 069743/0458
Security Interest
Recorded: 2024-12-19
Pages: 39
Assignors
CATALENT CTS (KANSAS CITY), LLC
Executed: 2024-12-18
REDWOOD BIOSCIENCE, INC.
Executed: 2024-12-18
R.P. SCHERER TECHNOLOGIES, LLC
Executed: 2024-12-18
CATALENT WELLNESS, LLC
Executed: 2024-12-18
CATALENT PHARMA SOLUTIONS, INC.
Executed: 2024-12-18
CATALENT WELLNESS NEW JERSEY, LLC
Executed: 2024-12-18
CATALENT MARYLAND, INC.
Executed: 2024-12-18
CATALENT GREENVILLE, INC.
Executed: 2024-12-18
CATALENT MICRON TECHNOLOGIES, INC.
Executed: 2024-12-18
CATALENT SAN DIEGO, INC.
Executed: 2024-12-18
CATALENT WELLNESS VIRGINIA, LLC
Executed: 2024-12-18
CATALENT USA PACKAGING, LLC
Executed: 2024-12-18
CATALENT PHARMA SOLUTIONS, LLC
Executed: 2024-12-18
Assignee
ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
245 PARK AVENUE, 44TH FLOOR, NEW YORK, NEW YORK, 10167
Covered Properties
(183)
Ingestible compositions containing an odoriferous oil
Formulations containing substituted imidazole derivatives
Chewable Soft Capsules Containing Ungelatinized Starch
Process for Formulating Fast Dispersing Dosage Forms Comprising at Least One Fish Gelatin Selected on the Basis of Molecular Weight
Fusion Antibodies
Non-Gelatin Soft Capsule System
Host Cells Containing Multiple Integrating Vectors
Nozzle Structure
System and Method for Dusting Soft Capsules
Apparatus and Method for Filling Containers
Molded Container with Opener and Method for Use
Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use
Fusion Antibodies
Genetically Modified Phage and Use Thereof
Process of Manufacturing a Stable Softgel Capsule Containing Microencapsulated Probiotic Bacteria
Oral Vaccine Fast-Dissolving Dosage Form Using Starch
Method for Producing Antibody Using "Naked" Expression Vector Expressing Type Ii Transmembrane Fusion Protein
Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use Thereof
Non-Gelatin Soft Capsule System
Two Phase Pharmaceutical Delivery System
Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate
Antibody Specific for CD22 and Methods of Use Thereof
Abuse Resistant Capsule
Veterinary Decorin Compositions and Use Thereof
Shell-Forming Compositions for Soft Capsules and Soft Capsules
Encased-Pellet Tablets
Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate
Stable Montelukast Solution
Compounds and Methods for Producing a Conjugate
Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof
Antibody Specific for CD22 and Methods of Use Thereof
Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use
Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same
Method for Producing Antibody Using "Naked" Expression Vector Expressing Type Ii Transmembrane Fusion Protein
Multiple-Fluid Injection Pump
Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate
Abuse Resistant Capsule
Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate
Methods for Manufacturing Encapsulated Granular Material, Methods for Drying Coating Materials, and Fluidized Bed Dryers
Host Cell for Producing Proteins
Process for Recovery of Waste Gel-Mass from Softgel Manufacturing Process
Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use Thereof
Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate
Antibody Conjugates and Methods of Making and Using the Same
Capsule Dispensing Container
Anti-CD22 Antibody-Maytansine Conjugates and Methods of Use Thereof
Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate
Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same
Anti-HER2 Antibody-Maytansine Conjugates and Methods of Use Thereof
Anti-CD22 Antibody-Maytansine Conjugates, Combinations, and Methods of Use Thereof
Application:
16/216,233 →
Publication:
US 2019/0201541
Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate
Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate
Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same
Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate
Multifunctional Protein Molecules Comprising Decorin and Use Thereof
A Method to Relieve Stress in Capsule Shells to Reduce Propensity to Break
Accelerated Drying of Soft Capsules in a Controlled Environment
Multiple-Fill/Chamber Softgel Die
Antibody Conjugates and Methods of Making and Using the Same
Abuse Resistant Capsule
System for Recovery of Waste Gel-Mass From Softgel Manufacturing Process
Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate
Formulation for Oral Delivery of Proteins, Peptides and Small Molecules with Poor Permeability
Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same
Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate
Pharmaceutical Dosage Form for an Emulsion of Simethicone and Loperamide
Enteric Softgel Capsules
Enteric Softgel Capsules
Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate
Solid or Semisolid Lipid Based Dosage Form Stabilization Through Curing and Addition of Low Hlb Surfactant(S)
Sulfatase-Cleavable Linkers for Antibody-Drug Conjugates
Apparatus and Process for Secondary Encapsulation of Solid Inclusions Using the Rotary Die Process
Vectors for Protein Manufacture
Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same
Decorin Compositions and Use Thereof
Application:
17/366,284 →
Publication:
US 2022/0073579
Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof
Antibody Specific for Mucin-1 and Methods of Use Thereof
Antibody Specific for CD22 and Methods of Use Thereof
Glycoside-Containing Peptide Linkers for Antibody-Drug Conjugates
Application:
17/423,796 →
Publication:
US 2022/0226490
Improved Api Stability in Softgels
Application:
17/438,335 →
Publication:
US 2022/0175683
Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate
Anti-CD25 Antibody-Maytansine Conjugates and Methods of Use Thereof
Glycoside Dual-Cleavage Linkers for Antibody-Drug Conjugates
Antibody Conjugates and Methods of Making and Using the Same
Formulation for Oral Delivery of Proteins, Peptides and Small Molecules with Poor Permeability
Camptothecine Antibody-Drug Conjugates and Methods of Use Thereof
Mini Softgel Naproxen Composition
Application:
17/582,616 →
Publication:
US 2022/0233452
Analytical Method
Mini Softgel Naproxen Composition
Application:
17/594,677 →
Publication:
US 2022/0202751
Delayed Release Softgel Capsules
Application:
17/596,059 →
Publication:
US 2022/0354800
Formulation for Oral Delivery of Proteins, Peptides and Small Molecules with Poor Permeability
Application:
17/602,915 →
Publication:
US 2022/0249468
Enteric Proton Pump Inhibitor Softgel Capsule
Application:
17/627,273 →
Publication:
US 2022/0249455
Softshell Capsule Formulations, and Methods of Preparation and Use Thereof
Application:
17/629,126 →
Publication:
US 2022/0280436
Antibody Specific for GPC3 and Methods of Use Thereof
Multifunctional Protein Molecules Comprising Decorin and Use Thereof
Anti-CD37 Antibody-Maytansine Conjugates and Methods of Use Thereof
Application:
17/760,989 →
Publication:
US 2023/0059250
Non-Animal Softgel Capsule Formulations, Methods of Preparation, and Methods of Use Thereof
Application:
17/767,523 →
Publication:
US 2024/0091161
Suppository Capsule
Application:
17/772,695 →
Publication:
US 2022/0378697
Delayed Release Softgel Capsules in Higher Ph Environment
Application:
17/772,698 →
Publication:
US 2022/0400724
Abuse Resistant Capsule
Hydrazinyl-Indole Compounds and Methods for Producing a Conjugate
Application:
17/874,122 →
Publication:
US 2023/0068124
Softgel Capsules
Application:
17/910,999 →
Publication:
US 2023/0172864
Two Part Rotary Die Encapsulation System
Delayed Release Softgel Capsules
Application:
17/928,955 →
Publication:
US 2023/0225980
Nucleic Acid Constructs for Protein Manufacture
Application:
18/007,568 →
Publication:
US 2023/0212590
Cell Lines with Multiple Docks for Gene Insertion
Application:
18/007,602 →
Publication:
US 2023/0227858
Modified Release Softgel Capsules
Application:
18/031,669 →
Publication:
US 2023/0390210
Delayed Release Softgel Capsules
Application:
18/036,207 →
Publication:
US 2023/0404927
Delayed Release Softgel Capsules
Application:
18/036,209 →
Publication:
US 2023/0404926
Camptothecine Antibody-Drug Conjugates and Methods of Use Thereof
Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same
Data Analysis and Reporting Systems and Methods
Application:
18/140,780 →
Publication:
US 2023/0351305
Method of Differentiation of Pluripotent Stem Cells to Retinal Pigment Epithelium Cells
Application:
18/195,849 →
Publication:
US 2023/0365929
Enteric Bisacodyl Softgel Capsule
Application:
18/208,635 →
Publication:
US 2023/0414523
Antibody Conjugates and Methods of Making and Using the Same
Application:
18/243,482 →
Publication:
US 2024/0101975
Controlled Release Fill Compositions and Capsules Containing Same
Application:
18/248,415 →
Publication:
US 2023/0372252
Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates
Application:
18/268,919 →
Publication:
US 2024/0197907
Branched Linkers for Antibody-Drug Conjugates and Methods of Use Thereof
Application:
18/276,432 →
Publication:
US 2024/0148883
Phospholipids as Anion Chelating Agents in Pharmaceutical Formulations
Application:
18/284,916 →
Publication:
US 2024/0189241
Anti-CD37 Antibody-Maytansine Conjugates and Methods of Use Thereof
Application:
18/288,148 →
Publication:
US 2024/0245794
Methods of Controlling Cleavage of Formylglycine-Containing Polypeptides
Application:
18/290,536 →
Publication:
US 2024/0376509
Antibody-Drug Conjugates and Methods of Use Thereof
Application:
18/291,841 →
Publication:
US 2025/0121090
Antibodies and Antibody Conjugates Specific for Nectin-4 and Methods of Use Thereof
Application:
18/291,897 →
Publication:
US 2025/0101098
Antibody Conjugates Specific for Mucin-1 and Methods of Use Thereof
Application:
18/291,900 →
Publication:
US 2025/0152724
Systems and Methods for Providing Optimal Process Parameters for Fluid Bed Granulation Systems
Application:
18/300,905 →
Publication:
US 2024/0342673
Anti-CD25 Antibody-Maytansine Conjugates and Methods of Use Thereof
Application:
18/384,707 →
Publication:
US 2024/0360123
Softgel Capsule and Method of Marking a Softgel Capsule
Application:
18/516,295 →
Publication:
US 2024/0164990
Softgel Capsule and Method of Marking a Softgel Capsule
Application:
18/516,302 →
Publication:
US 2024/0165041
Protective Coating for Moisture Sensitive Pharmaceutical Compositions
Application:
18/567,236 →
Publication:
US 2024/0285539
Softgel Capsule
Application:
18/575,474 →
Publication:
US 2024/0315977
Humidity Control Device
Application:
18/575,489 →
Publication:
US 2024/0328712
Antibodies Having Humanized Framework Regions
Application:
18/578,669 →
Publication:
US 2024/0343818
Tumor-Associated Calcium Signal Transducer 2 (TACSTD2) Antibody-Maytansine Conjugates and Methods of Use Thereof
Application:
18/578,690 →
Publication:
US 2025/0121083
Methods of Using Antibody-Drug-Conjugates
Application:
18/579,065 →
Publication:
US 2024/0325556
Antibody Specific for Mucin-1 and Methods of Use Thereof
Application:
18/621,926 →
Publication:
US 2025/0084182
Sulfatase-Cleavable Linkers for Antibody-Drug Conjugates
Application:
18/628,075 →
Publication:
US 2024/0342303
Pharmaceutical Trials Systems and Methods
Application:
18/724,812 →
Publication:
US 2025/0069036
Enteric Softgel Capsules
Application:
18/802,287 →
Publication:
US 2024/0398716
Delayed Release Softgel Capsules in Higher Ph Environment
Application:
18/819,147 →
Publication:
US 2024/0415157
Coated Enteric Softgel Capsules
Application:
18/819,242 →
Publication:
US 2024/0423921
Modified Release Valproic Acid Softgel Capsule
Application:
18/838,825 →
Publication:
US 2025/0177312
Softgel Capsules and a Method for Preparing the Softgel Capsules
Method to Relieve Stress in Capsule Shells to Reduce Propensity to Break
Application:
18/908,883 →
Publication:
US 2025/0025377
Fast Dissolving Softgel Capsules
Application:
18/940,147 →
Publication:
US 2025/0057774
Camptothecine Antibody-Drug Conjugates and Methods of Use Thereof
Application:
18/958,957 →
Publication:
US 2025/0223302
Glycoside Dual-Cleavage Linkers for Antibody-Drug Conjugates
Application:
18/959,336 →
Publication:
US 2025/0179117
Suppository
Patent:
914,867 →
Application:
29/711,528 →
Humidity Control Device and System
Application:
63/217,445 →
Pharmaceutical Trials Systems and Methods
Application:
63/295,050 →
Data Analysis and Reporting Systems and Methods
Application:
63/336,035 →
Method of Differentiation of Pluripotent Stem Cells to Retinal Pigment Epithelium Cells
Application:
63/340,736 →
Antibody-Drug Conjugates and Methods of Use Thereof
Application:
63/344,932 →
Method of Differentiation of Pluripotent Stem Cells to Immune Cells
Application:
63/406,185 →
Systems and Methods for Aggregating Supply Orders for Pharmaceutical Trials
Application:
63/411,333 →
Osmotic Pharmaceutical Capsules
Application:
63/443,142 →
Method of Differentiation of Pluripotent Stem Cells to Hematopoietic Precursor and Stem Cells
Application:
63/449,506 →
Methods of Differentiation of Pluripotent Stem Cells into Mesenchymal Stromal Cells
Application:
63/449,513 →
Systems and Methods for Producing Batch Records for Pharmaceutical Trials
Application:
63/463,183 →
Ambroxol Liquid Formulation
Application:
63/471,352 →
Two-Plasmid System for AAV Vector Particle Production
Application:
63/472,155 →
Methods for Nucleic Acid Separation and Analysis
Application:
63/498,873 →
Adeno-Associated Virus Vectors
Application:
63/524,265 →
Softgel Capsule Including a Non-Steroidal Anti-Inflammatory Drug and Acetaminophen
Application:
63/533,473 →
Softgel Capsule Including a Non-Steroidal Anti-Inflammatory Drug and Acetaminophen
Application:
63/533,476 →
Dnase Co-Expression in Host Cells
Application:
63/536,279 →
Fast Dissolving Softgel Capsules Including Ibuprofen
Application:
63/538,952 →
Dual-Payload Antibody-Drug Conjugates and Uses Thereof
Application:
63/538,962 →
Tandem-Cleavage Linkers for Antibody-Drug Conjugates and Uses Thereof
Application:
63/538,972 →
Tandem-Cleavage Linkers for Antibody-Drug Conjugates and Uses Thereof
Application:
63/544,310 →
Capsules for Oral and Nasal Delivery of Pharmaceutical Products
Application:
63/545,340 →
Method of Differentiation of Pluripotent Stem Cells to Natural Killer Cells
Application:
63/561,673 →
Methods for Genetically Engineering Mammalian Cells Using Serial Delivery
Application:
63/562,006 →
Tablet and Method of Marking a Tablet
Application:
63/601,551 →
Tandem-Cleavage Linkers for Antibody-Drug Conjugates and Uses Thereof
Application:
63/605,310 →
Lentiviral Vectors Incorporating Linker and Tag Systems for Car Detection
Application:
63/641,846 →
Ipsc Hepatocyte Differentiation
Application:
63/641,901 →
Chromatography Methods
Application:
63/643,170 →
Methods for Manufacturing Immunotherapy Cells
Application:
63/657,655 →
Peg-Carbamate Linkers for Antibody-Drug Conjugates and Uses Thereof
Application:
63/674,593 →
Magnet-Based Light-Blocking Systems and Methods for Manufacturing Light-Sensitive Products
Application:
63/675,563 →
Methods for Improved Gene Insertion and Expression in Cell Lines
Application:
63/678,309 →
Antibody Conjugates and Methods of Making and Using the Same
Application:
63/684,168 →
Digital Tuning of Selectable Markers
Application:
63/689,183 →
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Additional Restricted Subsidiary Intellectual Property Security Agreement Supplement
Nov 21, 2014
From: REDWOOD BIOSCIENCE, INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 034414/0616 →
Assignment of Assignor's Interest
May 7, 2015
From: CATALENT PHARMA SOLUTIONS
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 035584/0858 →
Corrective Assignment to Correct the Assignor's Name Previously Recorded at Reel: 035584 Frame: 0858. Assignor(S) Hereby Confirms the Assignment.
May 11, 2015
From: CATALENT PHARMA SOLUTIONS, INC.
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 035704/0785 →
Conversion
Nov 22, 2016
From: R. P. SCHERER TECHNOLOGIES, INC.
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 040670/0027 →
Corrective Assignment to Correct the Assignee Address Previously Recorded at Reel: 027291 Frame: 0081. Assignor(S) Hereby Confirms the Assignment .
Mar 12, 2018
From: TIAN, WEI; MCLAUGHLIN, ROSIE
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 045558/0610 →
Change of Address of Assignee
Oct 30, 2018
From: R.P. SCHERER TECHNOLOGIES, LLC
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 047364/0237 →
Notice of Succession of Agency
May 17, 2019
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049217/0981 →
Supplemental Security Agreement
May 20, 2019
From: R.P. SCHERER TECHNOLOGIES, LLC; CATALENT PHARMA SOLUTIONS, LLC; REDWOOD BIOSCIENCE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049221/0673 →
Assignment of Assignor's Interest
Jan 27, 2020
From: R.P. SCHERER TECHNOLOGIES, LLC
To: CATALENT U.K. SWINDON ZYDIS LIMITED
Reel/Frame 051634/0928 →
Partial Release of Security Interest
Mar 23, 2021
From: JPMORGAN CHASE BANK, N.A.
To: R.P. SCHERER TECHNOLOGIES, LLC (F/K/A R.P. SCHERER TECHNOLOGIES, INC.); CATALENT PHARMA SOLUTIONS, LLC; CATALENT USA WOODSTOCK, INC. (FORMERLY KNOWN AS CARDINAL HEALTH 400, INC.)
Reel/Frame 055681/0049 →
Patent Security Agreement
Mar 31, 2021
From: CATALENT USA WOODSTOCK, INC.
To: CERBERUS BUSINESS FINANCE AGENCY, LLC, AS THE COLLATERAL AGENT
Reel/Frame 055778/0019 →
Assignment of Assignor's Interest
Apr 5, 2021
From: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT PHARMA SOLUTIONS, INC.
To: WOLVERINE BIOSCIENCES, LLC
Reel/Frame 055821/0051 →
Patent Security Agreement
Apr 9, 2021
From: WOLVERINE BIOSCIENCES, LLC
To: CERBERUS BUSINESS FINANCE AGENCY, LLC, AS COLLATERAL AGENT
Reel/Frame 055886/0460 →
Merger
Apr 19, 2021
From: WOLVERINE BIOSCIENCES, LLC
To: WOODSTOCK STERILE SOLUTIONS, INC.
Reel/Frame 055955/0975 →
Assignment of Assignor's Interest
Jun 25, 2021
From: DELPHI GENETICS
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 056673/0745 →
Release of Security Interest in Patent Collateral (019323/0302)
Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; R.P. SCHERER TECHNOLOGIES, LLC; R.P. SCHERER CORPORATION
Reel/Frame 069750/0933 →
Release of Security Interest in Patent Collateral (029007/0559)
Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT CTS (KANSAS CITY), LLC
Reel/Frame 069751/0195 →
Release of Security Interest in Patent Collateral (034414/0616))
Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: REDWOOD BIOSCIENCE, INC.
Reel/Frame 069751/0128 →
Release of Security Interest in Patent Collateral (049221/0673)
Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; R.P. SCHERER TECHNOLOGIES, LLC; REDWOOD BIOSCIENCE, INC.
Reel/Frame 069751/0100 →